European Society for Medical Oncology

Exscientia Business Update for Third Quarter 2023

Retrieved on: 
Thursday, November 9, 2023
Biotechnology, Pharmaceutical, Oncology, Health, Artificial Intelligence, Health Technology, Technology, Clinical Trials, Research, Drug design, GBP, NSCLC, IND, MALT1, ESMO, Ovarian cancer, International, GMT, EST, Congress, Head, European Society for Medical Oncology, G&A, PKC, Colorectal cancer, Acute leukemia, Acquisition, Federal Reserve Bank, BMS, Growth, CDK7, ID, Risk, Bristol Myers Squibb, Jaundice, Merck Group, Pancreatic cancer, AlphaFold, Sumitomo Pharma, Lung cancer, LSD1, USD, AI, Berlin, Patient, Toxicity, AML, Automation, Pharmaceutical industry, Medical imaging, Rare-earth element, Fine chemical, Cryptocurrency, Bank, Sanofi

Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the third quarter of 2023, are summarised below.

Key Points: 
  • Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the third quarter of 2023, are summarised below.
  • Exscientia will host a conference call Thursday, November 9 at 1:30 p.m. GMT / 8:30 a.m. EST.
  • A replay will be available for 90 days under “Events and Presentations” in the “Investors and Media” section of the Exscientia website .
  • The increase in revenue quarter over quarter was primarily due to $8.38 million in revenue recognised from the projects that Exscientia and BMS mutually determined not to proceed with further development of under the BMS collaboration.

Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 7, 2023
Novartis Institute for Tropical Diseases, Trial of the century, AACR, ESMO, Progression-free survival, Biomedical Research, Congress, European Society for Medical Oncology, PFS, Conference, GAAP, Research, R, Ribociclib, ESR1, Novartis, Clinical trial, Silicon Valley Bank, Cancer, Oncology, CBR, Table, Patient, Breast, SAN, Pharmaceutical industry, Cryptocurrency, Medical imaging, G&A

Presented palazestrant Phase 2 monotherapy clinical study results as an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, on October 22, 2023.

Key Points: 
  • Presented palazestrant Phase 2 monotherapy clinical study results as an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, on October 22, 2023.
  • Non-GAAP R&D expenses were $16.7 million for the quarter ended September 30, 2023, excluding $2.8 million non-cash stock-based compensation expense.
  • Non-GAAP G&A expenses were $2.6 million for the quarter ended September 30, 2023, excluding $1.3 million non-cash stock-based compensation expense.
  • Non-GAAP G&A expenses were $4.1 million for the quarter ended September 30, 2022, excluding $1.5 million non-cash stock-based compensation expense.

Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Tuesday, November 7, 2023
VISTA, Research, Insurance, Research and development, The Year's Best Science Fiction: Twenty-Seventh Annual Collection, Northwest Biotherapeutics, ESMO, CD28, Therapy, Society for Immunotherapy of Cancer, VSIG4, Active, Safety, Conference, Translation, MBA, R, Protein, Pharmacokinetics, SITC, Immunotherapy, Sensei, Neoplasm, CD39, Cytokine release syndrome, Annual general meeting, Kinetics, CET, Tumor microenvironment, Society, Cancer, European Society for Medical Oncology, Patient, Administration, MS, Toxicity, Pharmaceutical industry, Vaccine, Cryptocurrency, Antibody, Science, Survival

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter ended September 30, 2023, and provided recent business updates.

Key Points: 
  • On October 23, 2023, Sensei presented a trial-in-progress poster from the Phase 1/2 clinical trial for SNS-101 at the European Society for Medical Oncology Congress (ESMO) 2023.
  • On November 1, 2023, Sensei announced the announced the appointment of Stephanie Krebs, MS, MBA, as Chief Business Officer.
  • General and Administrative (G&A) Expenses: G&A expenses were $3.9 million for the quarter ended September 30, 2023, compared to $4.8 million for the quarter ended September 30, 2022.
  • Net Loss: Net loss was $7.1 million for the quarter ended September 30, 2023, compared to $13.4 million for the quarter ended September 30, 2022.

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023
Research, ESMO, Food, DAR, HER2, Congress, G&A, Conference, European Society for Medical Oncology, R, B7-H4, ADC, Webcast, Cancer, Spacecraft, Merck Group, Oncology, GSK plc, GSK, Safety, Conference call, Therapy, Patient, Sodium-dependent phosphate transport protein 2B, Lifting, MRSN, Pharmaceutical industry, Fine chemical

ET

Key Points: 
  • ET
    CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the third quarter ended September 30, 2023.
  • In the third quarter of 2023, Mersana received $6 million in milestone payments from this agreement.
  • Mersana incurred $8.2 million in restructuring expenses for the third quarter of 2023 related primarily to severance-related costs and contract termination expenses.
  • ET to discuss business updates and its financial results for the third quarter of 2023.

Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 7, 2023
Research, European Organisation for Research and Treatment of Cancer, Treatment, Ipilimumab, Record, Melanoma, Viral load, OS, Neoplasm, PIWIL1, BRAF, Sale, ESMO, EORTC, HIV, Circulating tumor DNA, World Games, The New England Journal of Medicine, Cancer, Patient, DNA, Nivolumab, Congress, CTA, MAD, Insming, Oncology, RFS, PRAME, Nivolumab/relatlimab, TCR International, European Society of Gynaecological Oncology, IND, SVP, TCR, Gastrointestinal cancer, European Society for Medical Oncology, Observation, Senior, Infection, Book, James A. Schlipmann Melanoma Cancer Foundation, HBV, Pharmaceutical industry, Cryptocurrency, Medical imaging, USD, IMC, Immunocore

& ROCKVILLE, Md., US, 07 November 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, today announced its financial results for the third quarter ended September 30, 2023, and provided a business update.

Key Points: 
  • & ROCKVILLE, Md., US, 07 November 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, today announced its financial results for the third quarter ended September 30, 2023, and provided a business update.
  • Commercial sales have increased in the United States and European countries, including France, Germany and Italy, during the third quarter.
  • Since the beginning of 2023, we have launched KIMMTRAK in Austria, Israel, Italy, Finland, Switzerland and Belgium, and have recently reached price agreements with Canada and Australia.
  • Cash and cash equivalents were £364.0 million ($444.5 million) as of September 30, 2023, compared to £332.5 million as of December 31, 2022.

Xencor Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, CLDN3, Ovarian cancer, CD28, Telephone, STEAP1, OMERS, CLDN4, Sale, Vir, ESMO, Amgen, Cytokine, Gilead Sciences, Antibody, Part, Safety, Cancer, Investment, Patient, Congress, G&A, Prostate cancer, CTA, ENPP3, CLDN6, Liver disease, Genentech, European Society for Medical Oncology, CLDN9, Tafasitamab, IND, CD3, Colorectal cancer, R, Environment, Ravulizumab, Lung cancer, PARP, Vaccine, Pharmaceutical industry, Medical imaging, Rare-earth element, Cryptocurrency, Omeros, Janssen, MorphoSys, Alexion, Astellas Pharma

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a review of recent business and clinical highlights.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a review of recent business and clinical highlights.
  • Total revenue for the third quarter ended September 30, 2023 was $59.2 million, compared to $27.3 million for the same period in 2022.
  • Decreased net loss in the third quarter of 2023 compared to 2022 is primarily due to additional income earned.
  • ET (1:30 p.m. PT) to discuss the third quarter 2023 financial results and provide a corporate update.

Sermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete Remission in a Metastatic Breast Cancer Patient Participating in ELAINE-1 Trial

Retrieved on: 
Monday, November 6, 2023
Science, Breast, Report, ESMO, Progression-free survival, Therapy, Metastatic breast cancer, RL, Congress, European Society for Medical Oncology, Cyclin-dependent kinase 4, Conference, Breast cancer, Research, Cancer, Estrogen receptor alpha, Poster, JCO, Sheba Medical Center, ESR1, Fuchs, Prognosis, RM, Oncology, Estrogen, Clinical Cancer Research, Mortality, Patient, Fulvestrant, Mutation, Pharmaceutical industry, Medical imaging, Liquor, Woman, Incidence

The open-access case report, “ Lasofoxifene Monotherapy Induces Durable Complete Remission in a Patient with ER+, HER2- Metastatic Breast Cancer with an ESR1 Mutation ,” details a patient result that was reported during Sermonix’s Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE-1, NCT03781063) study.

Key Points: 
  • The open-access case report, “ Lasofoxifene Monotherapy Induces Durable Complete Remission in a Patient with ER+, HER2- Metastatic Breast Cancer with an ESR1 Mutation ,” details a patient result that was reported during Sermonix’s Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE-1, NCT03781063) study.
  • The case was previously presented as a poster and brief talk at the annual Metastatic Breast Cancer Research Conference in September 2022.
  • Topline results from the ELAINE-1 trial, including this patient, were reported at the European Society for Medical Oncology (ESMO) Congress 2022.
  • 5Jeselsohn R, De Angelis C, Brown M, et al: The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer.

Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update

Retrieved on: 
Thursday, November 2, 2023
Neoplasm, Research, NSCLC, Biomarker, Pembrolizumab, Betta, Castration, HIV disease progression rates, Cetuximab, Partnership, NRG1, Cancer, Drug design, PSA, ESMO, Head, Prostate cancer, Abstract (summary), Pancreatic cancer, ORR, Douglas BTD Destroyer, Safety, PDAC, Patient, EAP, Eli Lilly and Company, Congress, ADT, Clinical trial, CT, Oncology, European Society for Medical Oncology, Toxic leukoencephalopathy, FDA, Lilly, CD3, Aes, HER2, Afatinib, RECIST, Lung cancer, MET, BLA, FTD, Mutation, EGFR, Pharmaceutical industry, Life insurance, Vaccine, Medical imaging, Telescope, Bank, Tutoring, Birth control, CRPC, HNSCC, Incyte, Meru Networks

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the third quarter and provided a business update.

Key Points: 
  • In the planned trial, patients will be randomized to petosemtamab monotherapy or investigators’ choice of single agent chemotherapy or cetuximab.
  • Merus also continues to enroll patients with previously untreated advanced PD-L1+ HNSCC with petosemtamab 1500 mg in combination with Keytruda®.
  • Initial safety data from this single arm cohort may support the initiation of a first-line registration trial with this combination.
  • Merus achieved a milestone and received a payment of $2.5 million related to the advancement of this program in the third quarter of 2023.

Regeneron Reports Third Quarter 2023 Financial and Operating Results

Retrieved on: 
Thursday, November 2, 2023
CSU, DLBCL, Bispecific monoclonal antibody, FDA, Adolescence, American College, Ageing, CD3, ESMO, Food, Multiple myeloma, CD20, Fast Track, ACG, Congress, European Society for Medical Oncology, DME, Symantec Endpoint Protection, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, American College of Gastroenterology, The Lancet, Ministry, Ministry of Health (Kuwait), CRL, MHLW, Ministry of Health, Labour and Welfare, Oncology, Sanofi, Safety, Atopic dermatitis, CSCC, European, Patient, BCMA, Chronic obstructive pulmonary disease, COPD, Dupilumab, BLA, Pharmaceutical industry, Medical device, Vaccine, C5, Regeneron Pharmaceuticals, Health, EU

"Our third quarter financial results reflect robust execution across the enterprise, including notable pipeline advances and strong commercial performance," said Robert E. Landry, Executive Vice President, Finance and Chief Financial Officer of Regeneron.

Key Points: 
  • "Our third quarter financial results reflect robust execution across the enterprise, including notable pipeline advances and strong commercial performance," said Robert E. Landry, Executive Vice President, Finance and Chief Financial Officer of Regeneron.
  • These results were also presented at the 23rd EURETINA Congress in October 2023.
  • The Company announced that Robert E. Landry, Executive Vice President, Finance and Chief Financial Officer of Regeneron, will retire in February 2024.
  • Christopher Fenimore, current Senior Vice President, Head of Accounting and Controller at Regeneron, will succeed Mr. Landry as Chief Financial Officer upon his retirement.

Innovative Cellular Therapeutics (ICT) Presented Updated Data of the China-IRB Study of GCC19CART in Metastatic Colorectal Cancer at European Society for Medical Oncology (ESMO) Congress 2023

Retrieved on: 
Tuesday, October 31, 2023
Survival, CAR, IRB, ESMO, DCR, Diarrhea, Neurotoxicity, Congress, SD, Cytokine release syndrome, Oncology, ORR, RECIST, European Society for Medical Oncology, CRS, ICT, Patient, OS, Pharmaceutical industry

ICT presented updated data from its China-IRB study of GCC19CART, its lead product candidate from the Company’s CoupledCAR® technology, being developed to treat patients with relapsed/refractory metastatic colorectal cancer (R/R mCRC) in a poster presentation.

Key Points: 
  • ICT presented updated data from its China-IRB study of GCC19CART, its lead product candidate from the Company’s CoupledCAR® technology, being developed to treat patients with relapsed/refractory metastatic colorectal cancer (R/R mCRC) in a poster presentation.
  • Presentation details were as follows:
    This presentation highlights updated survival data from the 21 subjects who were enrolled in two dose escalation groups in IRB-approved studies in China.
  • The median OS is approximately 24 months in dose level 2 with 4 of the 8 patients still alive.
  • The Company’s Phase 1 study of GCC19CART is enrolling patients with R/R mCRC at multiple sites in the U.S.